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ABSTRACT
Lung cancer is rare disease in patients under 25 years 
of age. It typically occurs in older patients with a his-
tory of tobacco use. This case concerns a 20-year-old 
man with no history of tobacco use who complained 
of several months of cough and lower back pain and 
an 11.3-kg weight loss. He was treated for pneumonia 
after a chest radiograph showed total opacification 
of the right lung. Computed tomography imaging 
subsequently revealed a superior right hilar mass 
and mediastinal lymphadenopathy. Further imaging 
studies showed diffuse metastatic disease. Mediasti-
nal biopsy showed poorly differentiated epithelioid 
tumour with desmoplastic stromal reaction, neutro-
phil infiltration, and squamous differentiation. Tissue 
immunostaining confirmed a non-small-cell lung 
cancer. Unfortunately, despite aggressive therapy, 
the patient’s disease progressed, and he died within 9 
months. In this paper, we hope to illustrate the unique 
challenges in diagnosing and treating young patients 
with metastatic lung cancer.
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1.  INTRODUCTION
Lung cancer is the leading cause of death for men and 
women in the United States, surpassing deaths from 
breast, prostate, and colon cancer 1. The age-adjusted 
incidence for 2006 reveals that lung cancer is the 
number one cause of death for men over the age of 
40 and for women over the age of 60 1. Increasing age 
and tobacco use constitute the strongest risk factors 
for lung cancer. Young patients under 25 years of 
age without a history of tobacco use, environmental 
exposures, or genetic predisposition are only rarely 
diagnosed with lung cancer. Non-small-cell lung 
cancer (n s c l c ) typically presents at a more advanced 
stage and carries a poor prognosis.
2.  CASE DESCRIPTION
A 20-year-old man with no history of tobacco use 
presented with a several-months’ history of cough 
and lower back pain, and an 11.3-kg weight loss. 
Because of the persistent cough and development of 
hemoptysis, further imaging studies were obtained. 
A chest radiograph revealed total opacification of the 
right lung (Figure 1).
The patient was diagnosed with pneumonia and 
was started on antibiotics, but he did not improve.
Infectious serologies were negative. Computed 
tomography imaging of the thorax revealed a 7×7×8-
cm mass in the superior right hilum, total collapse of 
the right lung with post-obstructive atelectasis, and 
mediastinal lymphadenopathy (Figure 2). Further 
imaging revealed retroperitoneal lymphadenopathy, 
renal and pancreatic masses, skeletal metastases in 
the pelvis and vertebral bodies, and intraparenchymal 
brain metastases. Interestingly, both adrenal glands 
were spared.
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f i g u r e  1  Posteroanterior view of the chest demonstrates complete 
opacification of the right hemithorax.57
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f i g u r e  2  Computed tomography imaging of the thorax, with contrast, reveals a poorly defined 7×7×8-cm superior hilar mass.
Placement of a right bronchial stent and medias-
tinoscopy with biopsy were performed. The biopsy 
revealed poorly differentiated epithelioid tumour with 
desmoplastic stromal reaction, neutrophil infiltration, 
and squamous differentiation (Figure 3). The tumour 
cells stained positive for epithelial membrane antigen, 
pancytokeratin, thyroid transcription factor 1, and cy-
tokeratins 8 and 7. Testing for epidermal growth factor 
receptor mutation and amplification was negative. 
Isochrome 12p was not detected. Serum β–human 
chorionic gonadotropin was 3.6 IU/L (normal range: 
0–0.6 IU/L) and alpha fetoprotein was 1.5 ng/mL 
(normal reading: <6 ng/mL). Testicular ultrasound 
was unremarkable. These findings confirmed a pri-
mary lung adenocarcinoma.
The patient was urgently treated with cisplatin and 
etoposide. Radiotherapy was also initiated to lung, 
spine, and pelvis. He improved clinically, but required 
several hospitalizations throughout chemotherapy. 
Ultimately, his disease progressed, and he died within 
9 months of the initial diagnosis.
3.  DISCUSSION
Lung cancer is the leading cause of cancer-related 
death worldwide, with n s c l c  accounting for 85% 
of all lung cancers 2. Lung adenocarcinoma has the 
highest incidence among lung cancer patients, with 
a sex-specific incidence of about 30% in men and 
37% in women in the United States 3. The strongest 
risk factors for lung cancer are tobacco use and age, 
although small-cell lung cancer and squamous cell 
lung cancer have a stronger association with tobacco 
use than does lung adenocarcinoma 3.
In patients under 25 years of age, n s c l c  is exceed-
ingly rare, having an incidence rate for 2002–2006 of 
0.3 per 100,000 4. The most common types of lung 
cancer in this group of patients are pleuropulmonary 
blastoma, germ-cell tumours (teratocarcinoma), carci-
noid, and metastatic cancer from a non-lung primary 5. 
In reference to n s c l c  occurring in young people, a 
higher incidence of adenocarcinoma is seen in female 
patients, and most cases show no history of tobacco 
use 6. This observation suggests that genetic factors 
may have a greater role in the development of cancer 
in this patient population. Genetic factors are known 
to play a role in the development of lung adenocarci-
noma, and familial genetic clustering of lung cancer 
has been found. Common gene mutations in KRAS, 
EGFR, and TP53 have been associated with a higher 
risk for development of lung adenocarcinoma. We do 
not know the KRAS status for this patient’s tumour.
Survival in this group of patients remains highly 
variable. Mizushima et al. found no difference in 
survival between lung adenocarcinoma patients less 
than and more than 30 years of age 6. Similarly, a ret-
rospective study of patients younger than 50 years of 
age compared with those older than 50 found no dif-
ference in survival or in time to disease progression 9. 
In contrast, two other studies found a worse prognosis 
for young patients with lung adenocarcinoma than for 
their older counterparts 10.
Because of the dearth of cases, data evaluating the 
effectiveness of treatment for lung cancer in patients 
f i g u r e  3  Biopsy of the mediastinal mass shows a poorly differenti-
ated carcinoma, non-small-cell type. (Courtesy Kevin Leslie, m d , of the 
Department of Pathology, Mayo Clinic Arizona; with permission)58
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under 25 years of age are limited. Combined modali-
ties of chemoradiation and surgical resection have 
been tried and compared. Bourke et al. studied lung 
cancer in patients less than 45 years of age, compar-
ing them with patients more than 45 years of age at 
three different geographic sites 11. In that study, lung 
cancer staging was demonstrated to be the factor 
most determinant for survival in patients less than 
45 years of age 11.
4.  CONCLUSIONS
Metastatic n s c l c  is rare in patients under the age of 25 
years. Additional malignancies to be considered for tho-
racic masses in this age group include germ cell tumours 
(teratocarcinoma), lymphoma, carcinoid, and metas-
tases from a non-lung primary cancer. The prognosis 
of metastatic n s c l c  in young patients remains dismal. 
Further clinical trials evaluating this group of patients 
with metastatic n s c l c  are desperately needed.
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